VEGFA and hepatocellular carcinoma: Additionally, bevacizumab (a humanized monoclonal antibody that sequesters VEGFA) in combination with atezolizumab (immune checkpoint inhibitor) was approved by the FDA in 2020 for the treatment of patients with unresectable or metastatic HCC.